15 hours Ago By ABMN Staff
Ultragenyx Pharmaceutical ( NASDAQ:RARE – Get Free Report ) ‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $95.00 price target on the biopharmaceutical company’s stock.
HC Wainwright’s price target suggests a potential upside of 117.14% from the company’s current price. Several other brokerages have also recently commented on RARE.
TD Cowen boosted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st.
JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.
00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th.
Royal Bank of Canada reissued an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.
00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $88.
46. Read Our Latest Stock Analysis on RARE Ultragenyx Pharmaceutical Trading Down 0.3 % Ultragenyx Pharmaceutical ( NASDAQ:RARE – Get Free Report ) last released its earnings results on Tuesday, November 5th.
The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.
05. The company had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.
28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.
93%. Ultragenyx Pharmaceutical’s quarterly revenue was up 42.3% on a year-over-year basis.
During the same period in the prior year, the firm posted ($2.23) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -6.
2 earnings per share for the current year. Insider Transactions at Ultragenyx Pharmaceutical In other news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.
76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.
76. The trade was a 7.48 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . Also, CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction on Tuesday, December 10th.
The shares were sold at an average price of $50.00, for a total value of $413,650.00.
Following the completion of the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Company insiders own 5.80% of the company’s stock.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical A number of hedge funds have recently made changes to their positions in the stock. True Wealth Design LLC acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $43,000. nVerses Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $33,000.
UMB Bank n.a. increased its position in shares of Ultragenyx Pharmaceutical by 58.
1% during the second quarter. UMB Bank n.a.
now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares during the period. Values First Advisors Inc. bought a new position in Ultragenyx Pharmaceutical during the third quarter worth $56,000.
Finally, Wilmington Savings Fund Society FSB acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at $83,000. 97.67% of the stock is currently owned by institutional investors.
Ultragenyx Pharmaceutical Company Profile ( Get Free Report ) Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. Recommended Stories Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.
com's FREE daily email newsletter ..
